TLR9 and cancer: Likewise, a bi-adjuvant neoantigen nanovaccine (banNV) was developed for potent cancer immunotherapy by co-delivering a peptide neoantigen (Adpgk) with two adjuvants (TLR 7/8 agonist R848 and TLR9 agonist CpG) (Figure 5C).